Boston Scientific Corporation
BSXBoston Scientific is building a diversified portfolio of must-have medical devices that ride long-term demographic and procedural growth.
Because this is a business embedded in hospitals, powered by aging patients, and quietly turning innovation into cash.
Business Model
Devices plus services
It designs and sells implantable and surgical devices that hospitals buy for high-value procedures.
Economic Engine
High cash generation
Nearly 69% gross margins and strong cash conversion turn procedure growth into real cash.
Long-Term Lens
Ecosystem durability
The key question is whether its device portfolio stays clinically essential as technology evolves.
On this page
Company Story
How do Boston Scientific Corporation's business model and economics hold up on a closer read?
Start with the business itself, then go one layer deeper into the model, the economics, and the long-term case.
“A high-margin, procedure-driven medical device franchise with durable growth tailwinds and improving profitability that could compound for decades.”
What does Boston Scientific Corporation actually do?
Boston Scientific makes medical devices that doctors use to treat heart disease, cancer, chronic pain, and other serious conditions.
- Implantable heart rhythm devices and cardiac tools
- Stents and catheters used to open blocked arteries
- Devices for urology, endoscopy, and pain management
Why it matters
It is tied to essential procedures
Many of its products are used in life-saving or quality-of-life improving procedures that patients cannot easily delay forever.
How does Boston Scientific Corporation make money?
It sells high-value medical devices to hospitals and clinics that are used during procedures.
- Revenue grows as procedure volumes rise
- New product launches expand into adjacent treatments
- Global sales teams work directly with physicians and hospital systems
Economic clue
69% gross margin
High gross margins suggest pricing power and specialized products rather than commodity equipment.
Why do long-term investors keep Boston Scientific Corporation on the radar?
It sits at the intersection of aging populations, rising chronic disease, and increasingly sophisticated medical procedures.
- Revenue has grown 14% per year on average over five years
- Earnings per share have grown nearly 30% per year over five years
- Margins are expanding as scale increases
Investor takeaway
Growth plus margin expansion
When revenue growth combines with improving margins, earnings can compound faster than sales.
Based on company financial statements.
Benchmark Comparison
How has Boston Scientific Corporation performed against common long-term benchmarks?
Once the business case is clear, compare the stock against broad market and alternative long-term baselines.
$1,805
+80.5% total return
$1,753
+75.3% total return
$2,975
+197.5% total return
$1,393
+39.3% total return
| Asset | Total Return | Dollar Value |
|---|---|---|
| BSX | +80.5% | $1,805 |
| S&P 500 | +75.3% | $1,753 |
| Gold | +197.5% | $2,975 |
| Bitcoin | +39.3% | $1,393 |
From Mar 5, 2021 to Mar 6, 2026. Historical price data based on company financial statements and market indices. Each card uses the same starting amount so the comparison stays apples-to-apples.
Investor Fit
How a first-time investor could frame Boston Scientific Corporation
Before going deeper, decide what kind of business this is, what it tends to suit, and what deserves monitoring over time.
This Can Fit If You Want
- Exposure to aging population and rising procedure volumes
- A profitable healthcare business with strong cash generation
- A company reinvesting for growth instead of paying dividends
Be Careful If You Expect
- High dividend income, it pays none
- A simple one-product story, this is a diversified portfolio
- Zero regulatory risk, medical devices face strict oversight
What To Watch Over Time
- Whether gross margin stays near or above 69%
- Sustained double-digit average annual revenue growth
- Disciplined acquisitions that enhance, not dilute, returns
Key Metrics
Which metrics matter most for Boston Scientific Corporation right now?
Three durable business metrics that matter more than day-to-day price moves.
14% per year
29.7% per year
69% gross margin
| Metric | Value | Context |
|---|---|---|
| Revenue Growth | 14% per year | Shows whether the business has been expanding fast enough to create more long-term value. |
| EPS Growth | 29.7% per year | Shows whether earnings per share are compounding for owners over time. |
| Margin Quality | 69% gross margin | Shows how much room the business has to fund growth, absorb shocks, and stay profitable. |
Based on company financial statements.
Fundamentals
What do Boston Scientific Corporation's fundamentals say right now?
Core financial markers that explain how the business is performing beneath the stock price.
6.4% ROIC
69.0% gross margin
18.2% FCF margin
Stable to shrinking
| Metric | Value | Interpretation |
|---|---|---|
| Capital Efficiency | 6.4% ROIC | The business is currently showing poor capital efficiency. |
| Profitability | 69.0% gross margin | Healthy gross margins give the company room to invest, price competitively, and absorb shocks. |
| Cash Generation | 18.2% FCF margin | Free cash flow margin shows how much real cash the business keeps after funding operations and investment. |
| Ownership Trend | Stable to shrinking | The company is not currently diluting owners and may be buying back shares instead. |
Based on company financial statements.
Included In Funds
Which ETFs and funds currently hold Boston Scientific Corporation?
Boston Scientific Corporation currently appears in these ETF and fund proxies.
SPY
SPDR S&P 500 ETF Trust
IWB
iShares Russell 1000 ETF
Questions & Answers
What questions come up most often about Boston Scientific Corporation?
Company-specific questions readers often ask about Boston Scientific Corporation.
Each entry answers a direct question about the business, the long-term thesis, or the risks that matter over time.
Boston Scientific designs and sells medical devices that doctors implant or use during procedures to treat heart disease, chronic pain, cancer, and other serious conditions.
Decision Framing
Secondary context after the long-term thesis
Shorter-horizon context and comparison tools, after the core long-term read.
Shorter-horizon price moves, two-sided debate, and comparison tools live here so the page stays anchored on business quality, durability, and BinaPrint fit first.
Investment Thesis
Bull vs Bear
Two-sided framing before any decision.
Current argument weight is balanced.
Bull case
What can work
Aging populations globally mean more heart disease, vascular blockages, and chronic pain, all of which require devices that Boston Scientific already sells.
High gross margins of 69% provide room to invest heavily in research while still expanding operating margins, creating a virtuous cycle of innovation and profit.
Five-year average revenue growth of 14% and earnings growth near 30% show that management has translated product momentum into shareholder value.
Procedure-based demand is resilient over long periods because many treatments are medically necessary, not discretionary consumer purchases.
Bear case
What can break
A breakthrough non-invasive therapy or drug could reduce the need for implanted devices in key categories like heart rhythm management or vascular intervention.
Healthcare cost pressure from governments and insurers could squeeze pricing, pushing gross margins down from the current 69% level.
Regulatory setbacks or product safety issues could halt sales of major devices and damage physician trust for years.
Large competitors with deeper pockets could outspend Boston Scientific in research, eroding its share in core markets.
Risk Radar
Key Risks
Where downside pressure can build.
Regulatory risk, medical devices require approvals and adverse events could lead to recalls affecting major product lines.
Pricing pressure, with 69% gross margin, even a 5 percentage point decline could meaningfully reduce operating profit.
Acquisition integration risk, as growth partly depends on buying and integrating new technologies successfully.
Sizing matters
Risks should be read as scenario inputs, not certainties. Position size and time horizon determine how much of this downside profile is acceptable.
Market Snapshot
Tactical context after the core long-term read.
- Price
- $71.35
- Daily move
- -2.25%
Peer Set
A compact peer list for side-by-side context.
Next Actions
Explore planning scenarios or keep browsing similar companies.